Veloxis increases share capital in connection with exercise of warrants

Udgivet den 13-06-2016  |  kl. 08:00  |  

Company Announcement no. 13/2016

  

To: NASDAQ OMX Copenhagen A/S                                          Hørsholm, Denmark, 13 June 2016

  

 

Veloxis increases share capital in connection with exercise of warrants

 

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 11,695,434 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 1,169,543.40 as a consequence of the exercise of warrants by former employees of the company granted under the company's warrant program.

 

As a result of the employee's investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 4,141,239.

 

The subscription prices for the new shares are as follows (per share of nominal DKK 0.10):

 

6,911,734 shares DKK 0.35

4,783,700 shares DKK 0.36

 

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 169,907,388.10 divided into shares of DKK 0.10 each.

 

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

 

For more information, please contact:

Craig A. Collard                                        

President & CEO                                       

Phone: +1 919 524 4317                          

Email: cac@veloxis.com                            

  

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

 

Vedhæftede filer:

130616 Veloxis Announces Exercise of Warrants.pdf

Udgivet af: NPinvestordk

Seneste nyheder

17:49 Europa/lukning: Grønt med danske selskaber i den tunge ende
17:06 Fredagens obligationer: Rentedyk på ugens sidste dag og for hele ugen
17:05 Fredagens aktier: Ørsted gik til tops mens Novo, Mærsk og DSV trak ned
16:00 USA/åbning: Grøn åbning med teknologi i front - Intel stiger på opkøbsrygter
15:52 Novo er ramt af usikkerhed vurderer Sydbank: Prisforhandlinger bør ikke overraske
14:21 USA/tendens: Udsigt til stigninger på mindsket bekymring for renten
13:44 Europa/middag: Grønt Europa trods danske selskaber i den tunge ende
13:33 Novo Nordisk viser vægttab på lidt over 20 pct. med højdosisudgave af Semaglutid
13:21 Vestas udpeger ny chef for Development og henter ny juridisk chef hos FLSmidth
12:24 Obligationer/middag: Renten dykker let frem mod amerikansk industriproduktion - KORR
12:01 Trifork får løftet kursmålet til 105 kr. hos Carnegie
11:51 Obligationer/middag: Renten dykker let frem mod amerikansk industriproduktion
11:40 Aktier/middag: Ørsted vinder på købsanbefaling mens udsigt til våbenhvile sender Mærsk ned
11:34 Mærsk vil kun sejle igennem sikkert Rødt Hav: For tidligt at spekulere i timing
11:19 Netanyahu mødes med ministre for at stemme om våbenhvile i Gaza
11:06 Eurozonen: Inflationen tiltog til 2,4 pct. i december
10:53 NNIT-topchef: Grundlag for et godt 2025 trods tilpasning i USA og Europa
10:46 Ørsted får købanbefaling hos ABG: Negativ amerikansk påvirkning vil være begrænset
10:34 Columbus åbner døren for nyt ejerskab, fusion eller konsolidering
10:12 Houthibevægelsen signalerer pause for angreb i Det Røde Hav efter våbenhvile